Replies to post #800 on Lineage Cell Therapeutics Inc (LCTX)

[terry hallinan]

At some point in the future they have to start earning some money. I hope they can retain investors interest until that happens.

Oh, really?

The immortal unscholled physicist Stanford Ovshinsky scoffed for decades at the "threadbare scientists reading their papers to each other" as he and his followers became wealthy pursuing expensive research without product revenues:

https://tinyurl.com/yc5k7jqu

I watched forlornly on the sideline in disbelief as Stanford and his true believers became very wealthy.

Mike West appears cut from the same cloth but with the usual schooling of an accomplished scientist who has managed to build a small and growing community of a parent company with spun-off sateliites and fully independent biotechs that continually increase their intellectual property and wealth bereft of product revenues.

Revenues appear near from "beauty" treatments for AIDS patients if a CE Mark is obtained in Europe with sales perhaps beginning in the 2nd half of this year.

I am still discombobulated by people like this but at least I have a toe hold this time in blindingly futuristic science.

Best, Terry

[sokol]

Earn money? BTX will:

Renevia(®) successfully met the primary endpoint in a European pivotal study
for the treatment of HIV-Associated Facial Lipoatrophy. Treated patients
retained approximately 100% of transplanted volume at 6 months and there were
no device related serious adverse events noted during the trial.

BioTime plans to submit the Renevia(®) application for CE Marking later this
quarter with an expected approval in the second half of 2018. As the company
has previously reported, BioTime views the European trial as a gateway into a
larger multibillion-dollar market opportunity, like cosmetic facial
aesthetics. Currently, the U.S. facial fat transfer and dermal facial filler
market is estimated to be over 4 billion dollars and growing at or near
double digits.